FierceBiotech Names Compass Therapeutics a 2018 “Fierce 15” Biotech Company
CAMBRIDGE, Mass., Oct 2, 2018 — Compass Therapeutics, a biotechnology company committed to the ambitious goal of comprehensively drugging the human immune system, today announced that it has been named by FierceBiotech as one of 2018’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotech companies in the industry.
Compass, which completed its $132 million Series A financing this year, is forging a new approach to identifying antibody drug candidates that engage all targets in the biologically complex human immune synapse. The company’s antibody discovery platform enables the rapid identification of therapeutic candidates that engage with a broad range of epitopes and its StitchMabs™ bispecific screening platform enables the empirical, high-throughput identification of novel synergistic combinations and bispecifics. To date, the company’s integrated R&D approach has generated therapeutic candidates for more than 30 targets in cancer, inflammation and autoimmune disease. More than 15 of them are now advancing through preclinical development.
“We’re honored that the editors of FierceBiotech have recognized Compass for our pioneering approach to antibody-based therapeutics,” said Thomas Schuetz, M.D., Ph.D., the company’s co-founder and chief executive officer. “We believe our empirical, unbiased approach to drug discovery will lead to therapeutics with new mechanisms to modulate the human immune system.”
The Fierce 15 celebrates the spirit of being “fierce”— championing innovation and creativity, even in the face of intense competition. Selection to the list is based on factors including the strength of a company’s technology, partnerships and venture backers and its competitive market position.
About Compass Therapeutics
Compass Therapeutics currently has more than 15 antibody, antibody combination and bispecific programs advancing through preclinical development, targeting multiple pathways of significance for the immune system. The company’s offices, labs and vivarium are based in Kendall Square in Cambridge, Mass. Compass currently has approximately 80 full-time employees.
FierceBiotechis the biotech industry’s daily monitor, providing the latest biotech news, articles and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 150,000 top biotech professionals rely on FierceBiotechfor an insider briefing on the day’s top stories. Signup is free at www.fiercebiotech.com/signup.
Compass Media Contact
Ten Bridge Communications